Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
复制标题
DOI：
10.1016/j.coph.2012.06.008
复制
发表时间：
2012-08
影响因子：
4
通讯作者：
O'Shea, John J.
中科院分区：
文献类型：
--
作者：
Kontzias, Apostolos;Kotlyar, Alexander;Laurence, Arian;Changelian, Paul;O'Shea, John J.
Cytokines are critical for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease. A major subset of immunoregulatory cytokines, roughly 60, use the type I and type II cytokine receptors and pharmacological targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases. These receptors rely on Janus family of kinases (Jaks) for signal transduction and recently the first Jak inhibitor has been approved by the FDA. Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacological agents.
登录
查看更多内容
影响因子：
158.5
作者：
Druker, Brian J.;Guilhot, Francois;Larson, Richard A.
通讯作者：
Larson, Richard A.
影响因子：
5.5
作者：
Conklyn, M;Andresen, C;Kudlacz, E
通讯作者：
Kudlacz, E
影响因子：
--
作者：
Fleischmann, Roy;Cutolo, Maurizio;Zwillich, Samuel H.
通讯作者：
Zwillich, Samuel H.
影响因子：
--
作者：
Kremer, Joel M.;Bloom, Bradley J.;Zwillich, Samuel H.
通讯作者：
Zwillich, Samuel H.
影响因子：
50.3
作者：
Hedvat M;Huszar D;Herrmann A;Gozgit JM;Schroeder A;Sheehy A;Buettner R;Proia D;Kowolik CM;Xin H;Armstrong B;Bebernitz G;Weng S;Wang L;Ye M;McEachern K;Chen H;Morosini D;Bell K;Alimzhanov M;Ioannidis S;McCoon P;Cao ZA;Yu H;Jove R;Zinda M
通讯作者：
Zinda M